Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global X FTSE Southeast Asia ETF (ASEA) vs Cassava Sciences Inc (FLNA) Price & Performance

Global X FTSE Southeast Asia ETFTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

Global X FTSE Southeast Asia ETF vs Cassava Sciences Inc — how do they compare? Global X FTSE Southeast Asia ETF trades at $21.43, while Cassava Sciences Inc trades at $0.93 (market cap $47.75M). The key difference: Global X FTSE Southeast Asia ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

ASEAFLNA
Sector
Sector/ThematicHealth
52-Week High
$21.53$4.64
52-Week Low
$16.86$0.87
Market Cap
$47.75M
Enterprise Value
-$34.93M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global X FTSE Southeast Asia ETF

ASEA stock trades at $21.43, showing minimal daily movement with a 0.14% gain. Technical indicators signal strong bullish momentum with moving averages unanimously positive and ADX readings above 50 indicating a strong trend. The stock faces immediate resistance at $22 with support clustered around $21. A dividend of $0.41 per share is scheduled for July 2026, providing long-term income potential for investors.

The bullish technical setup suggests potential for near-term upside toward resistance levels, though fundamental analysis is limited without current financial metrics. Investors should monitor upcoming earnings reports for revenue growth and profitability trends. Key risks include market volatility and the company's ability to maintain competitive positioning in its sector.

Cassava Sciences Inc

FLNA is trading at $0.9401, down 5.74% on the day, with a bearish technical signal from moving averages. The company shows consistent quarterly earnings beats but remains unprofitable with negative ROE of -55.79% and negative cash flow. Analyst sentiment is positive with 67% buy ratings, though the stock faces fundamental challenges with ongoing operational losses.

The outlook remains challenged by persistent losses and negative cash flow, though recent earnings beats and strong analyst support provide potential upside. Key risks include the company's ability to achieve profitability and sustain operations given current burn rate. The biotechnology focus on TSC-related epilepsy represents both opportunity and execution risk.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Global X FTSE Southeast Asia ETF

ASEA tracks the performance of the largest companies in Southeast Asia. It provides exposure to key emerging markets including Singapore, Indonesia, Thailand, and Malaysia, with a heavy focus on financials like DBS Group and Bank Central Asia.

Read more on ASEA

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA